Our Products

AGGRASTAT® - US GP IIb/IIIa inhibitor market - $400 million (AGGRASTAT® + two competitors)

TARDOXAL™ - in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet need

About Medicure

Medicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics.

History

Medicure was founded in 1997 as a cardiovascular focused research and development company. During the Company's first decade, the Company raised over $125 million and focused this investment on the advancement and clinical development of a novel cardioprotective drug for use in conjunction with bypass surgery and percutaneous coronary intervention. In 2008 this lead clinical program provided unsatisfactory results in its pivotal, 3,000 patient Phase III trial, sending the Company into a challenging period in its history. During this period, the Company focused its limited staff and resources on its commercial product, Aggrastat, while at the same time working to restructure the Company finances in a way that would preserve maximum possible benefit for shareholders and other key stakeholders. In July 2011 Medicure was able to complete a major restructuring of its debt and secured new finances to advance a renewed business plan for the Company. Based on this, the Company has emerged as a small but focused specialty pharmaceutical company. The commercial business is generating revenue to support operations and to make selected investments in the clinical advancement of new projects related to AGGRASTAT and, secondly, to TARDOXAL for neurological disorders.

Today

Medicure's core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT. Acquired in 2006, AGGRASTAT is experiencing renewed interest from hospitals and clinicians in the US due to its compelling clinical and economic evidence. The Company has an experienced commercial team dedicated exclusively to the marketing of AGGRASTAT.

AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous transluminal coronary angioplasty (PTCA) or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction (MI), or refractory ischemia/repeat cardiac procedure. For additional information and full Prescribing Information, health care professionals can visit the AGGRASTAT product website.

The US rights to Aggrastat are owned by Medicure's subsidiary, Medicure International, Inc. (Barbados) and the product is distributed in the United States by Medicure's US subsidiary, Medicure Pharma, Inc.

Medicure opportunistically looks at small molecule development opportunities and currently has development programs in the neurology and cardiology fields.

For more information on the Company and the risks and uncertainties involved in its business, please refer to the most recent Management Discussion and Analysis, as provided on a quarterly basis, and in the "Risk Factors" section of its most recent Form 20F. The Company's ability to continue in operation for the foreseeable future remains dependent upon the effective execution of its business development and strategic plans.